OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Rational development of combination therapies for biliary tract cancers
James J. Harding, Danny N. Khalil, Luca Fabris, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 1, pp. 217-228
Closed Access | Times Cited: 41
James J. Harding, Danny N. Khalil, Luca Fabris, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 1, pp. 217-228
Closed Access | Times Cited: 41
Showing 1-25 of 41 citing articles:
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
James J. Harding, Jia Fan, Do‐Youn Oh, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 7, pp. 772-782
Open Access | Times Cited: 126
James J. Harding, Jia Fan, Do‐Youn Oh, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 7, pp. 772-782
Open Access | Times Cited: 126
USP21 deubiquitinates and stabilizes HSP90 and ENO1 to promote aerobic glycolysis and proliferation in cholangiocarcinoma
Xiao Xu, Yananlan Chen, Shenye Shao, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 4, pp. 1492-1508
Open Access | Times Cited: 9
Xiao Xu, Yananlan Chen, Shenye Shao, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 4, pp. 1492-1508
Open Access | Times Cited: 9
IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma
Haijiao Yan, Qian Deng, Yu Meng, et al.
Cancer Biotherapy and Radiopharmaceuticals (2025)
Closed Access | Times Cited: 1
Haijiao Yan, Qian Deng, Yu Meng, et al.
Cancer Biotherapy and Radiopharmaceuticals (2025)
Closed Access | Times Cited: 1
N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-L1
Jing Li, Xiaohong Xu, Kaihao Xu, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
Jing Li, Xiaohong Xu, Kaihao Xu, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
Biliary tract cancer
Kjetil Søreide, Cristina Dopazo, Frederik Berrevoet, et al.
European Journal of Surgical Oncology (2024), pp. 108489-108489
Open Access | Times Cited: 6
Kjetil Søreide, Cristina Dopazo, Frederik Berrevoet, et al.
European Journal of Surgical Oncology (2024), pp. 108489-108489
Open Access | Times Cited: 6
Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies
Xianzhe Yu, Lingling Zhu, Ting Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Xianzhe Yu, Lingling Zhu, Ting Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Degradation of AZGP1 suppresses apoptosis and facilitates cholangiocarcinoma tumorigenesis via TRIM25
Hyeseon Yun, Hong‐Rae Jeong, Do Yeon Kim, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 3
Open Access | Times Cited: 5
Hyeseon Yun, Hong‐Rae Jeong, Do Yeon Kim, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 3
Open Access | Times Cited: 5
Non-Inflamed Tumor Microenvironment and Methylation/Downregulation of Antigen-Presenting Machineries in Cholangiocarcinoma
Naoshi Nishida, Tomoko Aoki, Masahiro Morita, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2379-2379
Open Access | Times Cited: 12
Naoshi Nishida, Tomoko Aoki, Masahiro Morita, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2379-2379
Open Access | Times Cited: 12
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma
Jasmin Elurbide, Leticia Colyn, María U. Latasa, et al.
Gut (2024) Vol. 74, Iss. 1, pp. 116-127
Closed Access | Times Cited: 4
Jasmin Elurbide, Leticia Colyn, María U. Latasa, et al.
Gut (2024) Vol. 74, Iss. 1, pp. 116-127
Closed Access | Times Cited: 4
Efficacy and safety of immune checkpoint inhibitors in advanced biliary tract cancer: a real-world study
Yichen Zheng, Jiamin Guo, Tianhui Ren, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Yichen Zheng, Jiamin Guo, Tianhui Ren, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
CXCL6 Reshapes Lipid Metabolism and Induces Neutrophil Extracellular Trap Formation in Cholangiocarcinoma Progression and Immunotherapy Resistance
He Tian, Ziyi Wang, Bin Xu, et al.
Advanced Science (2025)
Open Access
He Tian, Ziyi Wang, Bin Xu, et al.
Advanced Science (2025)
Open Access
Efficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study based on propensity score matching
Song Liu, Qingdong Wang, Yin Shunhang, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Song Liu, Qingdong Wang, Yin Shunhang, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Advancing biliary tract malignancy treatment: emerging frontiers in cell-based therapies
Jian‐Yang Ao, Mingtai Hu, Jinghan Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Jian‐Yang Ao, Mingtai Hu, Jinghan Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma
Yu Huang, Yulu Ye, Tingzhuang Yi, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Yu Huang, Yulu Ye, Tingzhuang Yi, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies
Daisaku Yamada, Shogo Kobayashi, Yuichiro Doki, et al.
International Journal of Clinical Oncology (2025)
Open Access
Daisaku Yamada, Shogo Kobayashi, Yuichiro Doki, et al.
International Journal of Clinical Oncology (2025)
Open Access
Gallbladder and biliary tract cancer burdens in China from 1990 to 2021 and projection to 2044: findings from the 2021 Global Burden of Disease study
Zhongyi Jiang, Qianwei Jiang, Pusen Wang, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Zhongyi Jiang, Qianwei Jiang, Pusen Wang, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study
Ziqi Ye, Y. Zhang, Jie Chen, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110344-110344
Closed Access | Times Cited: 9
Ziqi Ye, Y. Zhang, Jie Chen, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110344-110344
Closed Access | Times Cited: 9
Effect of different PD ‐1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma
Zhengqing Lei, Weihu Ma, Anfeng Si, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 6, pp. 611-622
Closed Access | Times Cited: 9
Zhengqing Lei, Weihu Ma, Anfeng Si, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 6, pp. 611-622
Closed Access | Times Cited: 9
Increased co-expression of PD1 and TIM3 is associated with poor prognosis and immune microenvironment heterogeneity in gallbladder cancer
Xing He, Yaorong Peng, Gui He, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Xing He, Yaorong Peng, Gui He, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma
Darren Cowzer, Jessica White, Joanne F. Chou, et al.
JCO Precision Oncology (2023), Iss. 7
Closed Access | Times Cited: 8
Darren Cowzer, Jessica White, Joanne F. Chou, et al.
JCO Precision Oncology (2023), Iss. 7
Closed Access | Times Cited: 8
Pemigatinib: A Review in Advanced Cholangiocarcinoma
James E. Frampton
Targeted Oncology (2024) Vol. 19, Iss. 1, pp. 107-114
Closed Access | Times Cited: 2
James E. Frampton
Targeted Oncology (2024) Vol. 19, Iss. 1, pp. 107-114
Closed Access | Times Cited: 2
Inhibition of CISD1 attenuates cisplatin-induced hearing loss in mice via the PI3K and MAPK pathways
Wenqi Dong, Yumeng Jiang, Qingxiu Yao, et al.
Biochemical Pharmacology (2024) Vol. 223, pp. 116132-116132
Closed Access | Times Cited: 2
Wenqi Dong, Yumeng Jiang, Qingxiu Yao, et al.
Biochemical Pharmacology (2024) Vol. 223, pp. 116132-116132
Closed Access | Times Cited: 2
Strategies to enhance the response of liver cancer to pharmacological treatments
José J.G. Marı́n, Rocı́o I.R. Macı́as, Maitane Asensio, et al.
AJP Cell Physiology (2024) Vol. 327, Iss. 1, pp. C11-C33
Closed Access | Times Cited: 2
José J.G. Marı́n, Rocı́o I.R. Macı́as, Maitane Asensio, et al.
AJP Cell Physiology (2024) Vol. 327, Iss. 1, pp. C11-C33
Closed Access | Times Cited: 2
Overcoming treatment resistance in cholangiocarcinoma: current strategies, challenges, and prospects
Jiayi Wang, Siyan Liu, Yi Cao, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 2
Jiayi Wang, Siyan Liu, Yi Cao, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 2
Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions
GuanBo Zhang, Jinsong Li, Gang Li, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
GuanBo Zhang, Jinsong Li, Gang Li, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
